← Back to Clinical Trials
Recruiting NCT06317714

Long-term Follow-up and Quality of Life of Patients Treated With Anticancer Drugs

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Oncology
Sponsor Institut Rafael
Study Type OBSERVATIONAL
Phase N/A
Enrollment 300
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2024-03-08
Completion 2027-03-08
Interventions
questionnaires

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Currently, aspects related to the effects of anticancer treatments and the quality of life of patients and their needs are still poorly documented at the Rafael Institute. Thus this study will meet a dual objective: (1) the establishment of a registry to collect data on the safety and effectiveness of innovative and expensive anticancer drugs when administered in real life and (2) a measurement quantitative quality of life of patients treated with these drugs.

Eligibility Criteria

Inclusion Criteria: * Age equal to or greater than 18 years (adult) * Patients treated with an anticancer drug included in the list of innovative/expensive therapies (protocol appendix) * Patients benefiting from non-pharmacological treatment at the Rafael Institute * Who understands the French language Exclusion Criteria: * \< 18 years old * Patient deprived of liberty, under guardianship or unable to give consent

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}